Hydroxyurea ( DrugBank: Hydroxyurea )

8 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
3	脊髄性筋萎縮症	3
13	多発性硬化症／視神経脊髄炎	1
19	ライソゾーム病	1
20	副腎白質ジストロフィー	1
65	原発性免疫不全症候群	1
85	特発性間質性肺炎	1
86	肺動脈性肺高血圧症	1
284	ダイアモンド・ブラックファン貧血	1

3. 脊髄性筋萎縮症

臨床試験数 : 237 / 薬物数 : 123 - (DrugBank : 29) / 標的遺伝子数 : 51 - 標的パスウェイ数 : 75

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00485511 (ClinicalTrials.gov)	June 2007	11/6/2007	A Trial of Hydroxyurea in Spinal Muscular Atrophy	A Randomized, Double-Blind, Placebo-Controlled Trial of Hydroxyurea in Spinal Muscular Atrophy	Spinal Muscular Atrophy	Drug: Hydroxyurea	Kaohsiung Medical University Chung-Ho Memorial Hospital	NULL	Completed	4 Years	N/A	Both		Phase 2/Phase 3	Taiwan
2	NCT00568802 (ClinicalTrials.gov)	January 2004	4/12/2007	A Pilot Therapeutic Trial Using Hydroxyurea in Type II and Type III Spinal Muscular Atrophy Patients	A Pilot Therapeutic Trial Using Hydroxyurea in Type II and Type III Spinal Muscular Atrophy Patients	Muscular Atrophy, Spinal	Drug: Hydroxyurea;Drug: Placebo to match hydroxyurea	Stanford University	NULL	Completed	1 Year	10 Years	All	27	Phase 1/Phase 2	United States
3	NCT00568698 (ClinicalTrials.gov)	January 2004	4/12/2007	A Pilot Therapeutic Trial Using Hydroxyurea in Type I Spinal Muscular Atrophy Patients	A Pilot Therapeutic Trial Using Hydroxyurea in Type I Spinal Muscular Atrophy Patients	Muscular Atrophy, Spinal	Drug: Hydroxyurea;Drug: Placebo to match hydroxyurea	Stanford University	NULL	Completed	N/A	2 Years	All	29	Phase 1/Phase 2	United States

13. 多発性硬化症／視神経脊髄炎

臨床試験数 : 3,340 / 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01103583 (ClinicalTrials.gov)	July 2011	13/4/2010	Hydroxyurea in Primary Progressive Multiple Sclerosis		Multiple Sclerosis	Drug: Hydroxyurea;Other: placebo	S. Andrea Hospital	NULL	Terminated	18 Years	60 Years	Both	33	Phase 2/Phase 3	Italy

19. ライソゾーム病

臨床試験数 : 899 / 薬物数 : 684 - (DrugBank : 99) / 標的遺伝子数 : 51 - 標的パスウェイ数 : 182

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00383448 (ClinicalTrials.gov)	September 2006	29/9/2006	HSCT for High Risk Inherited Inborn Errors	Treatment of High Risk, Inherited Lysosomal And Peroxisomal Disorders by Reduced Intensity Hematopoietic Stem Cell Transplantation	Adrenoleukodystrophy;Metachromatic Leukodystrophy;Globoid Cell Leukodystrophy;Tay Sachs Disease;Sandhoffs Disease;Wolman Disease;I-Cell Disease;Sanfilippo Syndrome;GM1 Gangliosidosis	Drug: Clofarabine;Procedure: Total body Irradiation;Drug: Melphalan;Biological: Hematopoietic Stem Cell Transplantation;Drug: Alemtuzumab;Drug: mycophenylate mofetil;Device: Cyclosporine A;Drug: Hydroxyurea	Masonic Cancer Center, University of Minnesota	NULL	Completed	N/A	70 Years	All	38	Phase 2	United States

20. 副腎白質ジストロフィー

臨床試験数 : 61 / 薬物数 : 90 - (DrugBank : 31) / 標的遺伝子数 : 23 - 標的パスウェイ数 : 126

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00383448 (ClinicalTrials.gov)	September 2006	29/9/2006	HSCT for High Risk Inherited Inborn Errors	Treatment of High Risk, Inherited Lysosomal And Peroxisomal Disorders by Reduced Intensity Hematopoietic Stem Cell Transplantation	Adrenoleukodystrophy;Metachromatic Leukodystrophy;Globoid Cell Leukodystrophy;Tay Sachs Disease;Sandhoffs Disease;Wolman Disease;I-Cell Disease;Sanfilippo Syndrome;GM1 Gangliosidosis	Drug: Clofarabine;Procedure: Total body Irradiation;Drug: Melphalan;Biological: Hematopoietic Stem Cell Transplantation;Drug: Alemtuzumab;Drug: mycophenylate mofetil;Device: Cyclosporine A;Drug: Hydroxyurea	Masonic Cancer Center, University of Minnesota	NULL	Completed	N/A	70 Years	All	38	Phase 2	United States

65. 原発性免疫不全症候群

臨床試験数 : 500 / 薬物数 : 614 - (DrugBank : 119) / 標的遺伝子数 : 92 - 標的パスウェイ数 : 217

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01962415 (ClinicalTrials.gov)	February 4, 2014	10/10/2013	Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT	A Phase II Study of Reduced Intensity Conditioning in Pediatric Patients and Young Adults =55 Years of Age With Non-Malignant Disorders Undergoing Umbilical Cord Blood, Bone Marrow, or Peripheral Blood Stem Cell Transplantation	Primary Immunodeficiency (PID);Congenital Bone Marrow Failure Syndromes;Inherited Metabolic Disorders (IMD);Hereditary Anemias;Inflammatory Conditions	Drug: Hydroxyurea;Drug: Alemtuzumab;Drug: Fludarabine;Drug: Melphalan;Drug: Thiotepa	Paul Szabolcs	NULL	Recruiting	2 Months	55 Years	All	100	Phase 2	United States

85. 特発性間質性肺炎

臨床試験数 : 627 / 薬物数 : 443 - (DrugBank : 120) / 標的遺伝子数 : 99 - 標的パスウェイ数 : 212

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03500731 (ClinicalTrials.gov)	April 19, 2018	30/3/2018	Lung and Bone Marrow Transplantation for Lung and Bone Marrow Failure	Lung Transplant in Tandem With Bone Marrow Transplant for Combined Lung and Bone Marrow Failure	Idiopathic Pulmonary Fibrosis;Emphysema or COPD	Biological: CD3/CD19 negative hematopoietic stem cells;Drug: Rituximab;Drug: Alemtuzumab;Drug: Fludarabine;Drug: Thiotepa;Drug: G-CSF;Drug: Hydroxyurea	Paul Szabolcs	NULL	Recruiting	18 Years	60 Years	All	8	Phase 1/Phase 2	United States

86. 肺動脈性肺高血圧症

臨床試験数 : 1,205 / 薬物数 : 684 - (DrugBank : 124) / 標的遺伝子数 : 100 - 標的パスウェイ数 : 193

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01950585 (ClinicalTrials.gov)	September 6, 2013	21/9/2013	Hydroxyurea in Pulmonary Arterial Hypertension	Hydroxyurea in Pulmonary Arterial Hypertension	Pulmonary Hypertension	Drug: Hydroxyurea	National Heart, Lung, and Blood Institute (NHLBI)	The Cleveland Clinic	Withdrawn	18 Years	110 Years	All	0	Early Phase 1	United States

284. ダイアモンド・ブラックファン貧血

臨床試験数 : 36 / 薬物数 : 95 - (DrugBank : 34) / 標的遺伝子数 : 23 - 標的パスウェイ数 : 126

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03653338 (ClinicalTrials.gov)	August 2, 2018	2/8/2018	T-Cell Depleted Alternative Donor Bone Marrow Transplant for Sickle Cell Disease (SCD) and Other Anemias	T-Cell Depleted, Alternative Donor Transplant in Pediatric and Adult Patients With Severe Sickle Cell Disease (SCD) and Other Transfusion-Dependent Anemias	Sickle Cell Anemia;Beta-thalassemia Major;Diamond-blackfan Anemia	Biological: CD3/CD19 depleted leukocytes;Biological: CD45RA depleted leukocytes;Drug: Hydroxyurea;Drug: Rituximab;Drug: Alemtuzumab;Drug: Fludarabine;Drug: Thiotepa	Paul Szabolcs	NULL	Recruiting	5 Years	40 Years	All	5	Phase 1/Phase 2	United States

先頭へ